

PRODUCT INFORMATION

| | |
|---|---|
| Common Name | BART, BIIB-037, BIIB037, aducanumab-avwa |
| Conjugate | Biotinylated |
| Synonyms | AAA;ABETA;ABPP;AD1;APPI;CTFgamma;CVAP;PN-II;PN2;preA4 |
| Applications | Flow Cyt |
| Endotoxin | Less than 1.0 EU/μg by the LAL method. For <1 EU/mg requirements, please contact us for customization. |
| Recommended Dilutions | Flow Cyt 1:100 |
| Formulation & Reconstitution | Lyophilized from sterile PBS, pH 7.4. Normally 5 % - 8% trehalose is added as protectants before lyophilization. Please see Certificate of Analysis for specific instructions of reconstitution. |
| Host Species | Homo sapiens |
| IgG type | Human IgG1 - kappa |
| Reactivity | Human |
| Target | APP |
| Uniprot ID | P05067 |
| Description | Biotinylated Anti-APP(aducanumab biosimilar) mAb |
| Delivery | 2-3 weeks |
| Storage&Shipping | Store at -20°C to -80°C for 12 months in lyophilized form. After reconstitution, if not intended for use within a month, aliquot and store at -80°C (Avoid repeated freezing and thawing). Lyophilized proteins are shipped at ambient temperature. |
| Background | Research grade biosimilar. Not for use in therapeutic or diagnostic procedures for humans or animals. |
| Usage | Research use only |

